肺癌免疫检查点抑制剂治疗反应、无进展生存和总生存的预测因素
本文综述了在非小细胞肺癌和小细胞肺癌中,免疫检查点抑制剂在初治和后续治疗中可改善客观缓解率、无进展生存和总生存,但仅部分未选择患者获益。文章讨论了已确立和新兴的生物标志物,用于预测哪些患者最可能从治疗中获得临床获益。
要点
- 免疫检查点抑制剂在肺癌一線及后线均改善ORR、PFS和OS。
- 仅部分未选择肺癌患者对免疫检查点抑制剂有反应。
- 识别预测临床获益的生物标志物是重要研究方向。
核心结论
- 免疫检查点抑制剂在肺癌中可改善客观缓解率、无进展生存和总生存,但仅部分未选择患者获益,需生物标志物预测获益人群。
研究设计与样本
- 综述,讨论来自已证明免疫检查点抑制剂对NSCLC和SCLC有效的临床试验中的已确立和新兴生物标志物。
主要发现
- 免疫检查点抑制剂在初治和后续治疗中均显示改善客观缓解率、无进展生存和总生存。
- 仅一部分未选择的肺癌患者对免疫检查点抑制剂治疗有反应。
临床怎么用
- 临床中需关注预测免疫检查点抑制剂获益的生物标志物,以识别最可能获益的肺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal antibodies that target immune checkpoint proteins, so-called immune checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in the treatment of lung cancer. Studies have revealed improved objective response rates, progression-free survival, and overall survival with immune checkpoint inhibitors when used in both first and subsequent-line settings. Unfortunately, only a subset of unselected patients with lung cancer responds to these therapies. An important area of ongoing research is to identify biomarkers that can predict which patients are most likely to derive clinical benefit. This review will discuss established and emerging biomarkers from some of the clinical trials that have demonstrated the efficacy of immune checkpoint inhibitors for the treatment of both NSCLC and SCLC.
引用
- Memmott RM, Wolfe AR, Carbone DP, et al. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021. PMID: 33845212. doi:10.1016/j.jtho.2021.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。